Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II PK/PD and safety study of LPRI-CF113 vs LF111 in healthy premenopausal women
jRCT2071240132Phase 2Recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LPRI-CF113 in dysmenorrhea (2 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Hoogland Score, Serum estradiol (E2) concentration and 6 more. Started Apr 2025; status: recruiting.
02
Drugs
LPRI-CF113
03
Conditions
dysmenorrhea
Beyond the preview
Go deeper on jRCT2071240132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240132.